Adaptive Biotechnologies

What Adaptive Biotechnologies does

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company founded in 2009 and headquartered in Seattle, Washington, that translates the genetics of the adaptive immune system into clinical diagnostics and therapeutic discovery tools. Its core commercial product is clonoSEQ, the first FDA-cleared next-generation sequencing assay for minimal residual disease (MRD) monitoring, currently reimbursed for multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and more recently mantle cell lymphoma (MCL) under Medicare. The clonoSEQ assay detects residual cancer cells in bone marrow or blood at a sensitivity of one in a million cells (10⁻⁶) and is ordered by oncologists and hematologists for treatment-response assessment and disease-progression monitoring, with test volume reaching 105,587 in 2025.

The company's second business line is its Immune Medicine Platform, which combines immunosequencing, proprietary TCR-antigen mapping, and AI/ML to decode T-cell and B-cell receptor sequences against disease-specific antigens. The platform underpins the immuneCODE database and supports pharma partnerships for target discovery and clinical-trial biomarkers, most notably two December 2025 agreements with Pfizer with up to $890 million in potential milestone payments.

Adaptive generates revenue primarily through clinical diagnostic testing services billed to Medicare and commercial payers at an average selling price of approximately $1,400 per clonoSEQ test, supplemented by biopharma services (MRD testing and immune monitoring for clinical trials) and non-exclusive immune-receptor data licensing agreements with pharmaceutical partners. The MRD business contributed $212 million of 2025 revenue and reached positive adjusted EBITDA of $15 million, while full-year 2025 total revenue reached $277 million (55% YoY growth). The company operates a U.S.-focused direct sales and CLIA-certified laboratory model, with plans to expand internationally through technology transfer partnerships and to separate the MRD and Immune Medicine businesses into two distinct entities by year-end 2026.

Name

Adaptive Biotechnologies

Legal name

Adaptive Biotechnologies Corporation

Website

https://adaptivebiotech.com

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Adaptive Biotechnologies is a Seattle-based, NASDAQ-listed biotechnology company that translates adaptive immune system genetics into clinical diagnostics and pharma discovery tools, anchored by its FDA-cleared clonoSEQ MRD test for blood cancers and an immune receptor data platform serving biopharma partners.

Ownership category

akta.pro rank

Product category

Clinical Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAAALAE

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAAAIAE

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAMAK

Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)

Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

SECONDARYHLAAAIAA

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Immune sequencing diagnostics
• Minimal residual disease testing
• T-cell receptor profiling
• Immune receptor mapping
• Clinical genomic diagnostics

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. MRD Testing (clonoSEQ): Revenue from clinical diagnostic testing services using clonoSEQ assay for minimal residual disease monitoring in blood cancer patients. Tests are ordered by oncologists and hematologists for patient monitoring during and after treatment. Q1 2026 MRD revenue was $67.1 million, representing 95% of total revenue.
2. Pharma Partnerships - Immune Receptor Licensing: Non-exclusive licensing agreements with pharmaceutical companies for T-cell receptor discovery and immune receptor data. December 2025 Pfizer agreements worth up to $890 million in potential milestone payments plus upfront payments. Includes target discovery partnership and data licensing for AI-driven drug discovery.
3. Biopharma Services: Services provided to pharmaceutical companies for clinical trials including MRD testing in drug development, immune monitoring, and clinical trial support. Growing pharma trial backlog supporting MRD-led growth.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Adaptive Biotechnologies translates the scale and precision of the adaptive immune system into clinical diagnostics and immune profiling products. Its core commercial offering is clonoSEQ, an FDA-cleared NGS-based minimal residual disease (MRD) test that detects and monitors residual cancer cells in blood and bone marrow for multiple myeloma, B-ALL, CLL, and other lymphoid malignancies. The company also operates an Immune Medicine Platform that maps T-cell receptors to disease-specific antigens, enabling data licensing and target discovery partnerships with pharmaceutical companies.

Product overview

Adaptive Biotechnologies operates a dual-segment business centered on its Immune Medicine Platform, which encompasses two core products: clonoSEQ and the Immune Medicine discovery business. clonoSEQ is an FDA-cleared NGS-based MRD test for measuring residual cancer cells in blood cancers, while the Immune Medicine Platform uses immune repertoire sequencing and AI-driven TCR-antigen models to support drug discovery and biopharma partnerships. The company recently announced plans to separate these two businesses into distinct entities. Key offerings include T-Detect COVID (a T-cell diagnostic for prior SARS-CoV-2 infection), immunoSEQ T-MAP COVID (a vaccine monitoring tool), and the newly launched Digital Biotechnologies subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

• clonoSEQ: FDA-cleared NGS-based MRD test for measuring residual disease in blood cancers including multiple myeloma, B-ALL, and CLL
• T-Detect
• immunoSEQ
• immuneCODE

Products and services

• clonoSEQ FDA-cleared NGS-based minimal residual disease (MRD) test that detects and monitors residual cancer cells in bone marrow and blood samples from patients with multiple myeloma, B-ALL, CLL, and other lymphoid malignancies at a sensitivity of 1 in 1,000,000 cells. Ordered by oncologists and hematologists, processed through Adaptive's CLIA-certified lab, and reimbursed by Medicare and commercial insurance.
• Immune Medicine Platform Proprietary immune repertoire sequencing platform that maps T-cell receptors (TCRs) to disease-specific antigens, enabling drug discovery partnerships and AI-driven target identification for immunology applications. Anchored by a database of over 6 million functional TCR-antigen pairs and used by pharmaceutical companies such as Pfizer for AI-driven drug discovery and TCR target identification.
• T-Detect COVID T-cell based clinical diagnostic test that detects prior SARS-CoV-2 infection by identifying virus-specific T-cell signatures in blood, offering higher sensitivity and durability than antibody serology testing.
• immunoSEQ T-MAP COVID Molecular T-cell monitoring tool for vaccine developers that maps TCRs to SARS-CoV-2 antigens, enabling quantitative measurement of T-cell immune response to vaccines and tracking of response persistence over time.

Quantifiable outcome

• Patients with undetectable MRD had nearly 7-fold decreased risk of disease progression compared to MRD-positive patients
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Pfizer Inc.coreStrategic or Co-development Partner · 15 December 2025Two non-exclusive licensing agreements: (1) T-cell receptor target discovery partnership for rheumatoid arthritis where Adaptive identifies disease-specific TCRs and Pfizer handles development and commercialization; (2) Data licensing agreement for Adaptive's proprietary TCR-antigen binding datasets to accelerate Pfizer's AI-driven drug discovery. Total potential milestone payments up to $890 million.
• NeoGenomicsminorStrategic or Co-development PartnerExclusive multi-year MRD collaboration announced in 2026 for liquid biopsy and NGS panel offerings. NeoGenomics will offer MRD testing services using Adaptive's technology.
• ACCC (Association of Community Cancer Centers)minorStrategic or Co-development PartnerSponsor partnership for MRD education initiatives targeting community oncology practices. Joint development of MRD Testing Implementation Roadmap for CLL and multiple myeloma.
• NCODA (National Community Oncology Dispensing Association)minorStrategic or Co-development PartnerPartnership for MRD education in community oncology. NCODA published Positive Quality Intervention for clonoSEQ in CLL.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Natera: Natera markets Signatera, a leading tumor-informed NGS-based MRD test used in solid tumor monitoring and clinical trials. It is the most direct competitor to Adaptive's clonoSEQ in the MRD testing category, serving oncologists and biopharma sponsors with overlapping clinical use cases.
• NeoGenomics: NeoGenomics provides oncology testing including liquid biopsy and NGS panels, and signed an exclusive multi-year MRD collaboration with Adaptive in 2026. It is both a partner and adjacent competitor in the community oncology MRD/liquid biopsy segment.
• Guardant Health: Guardant Health offers liquid biopsy-based oncology tests (Guardant360, Guardant Reveal MRD) for solid tumors. It competes with Adaptive in oncology diagnostics and shares the same hospital and biopharma customer base for cancer recurrence and monitoring.

Broad incumbents

• Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading provider of comprehensive genomic profiling in oncology. It overlaps with Adaptive's immune profiling and biopharma services and serves many of the same academic cancer centers and pharma sponsors at broader scale.
• Exact Sciences: Exact Sciences is a large cancer diagnostics company known for Cologuard and the Oncotype franchise. It is a broader incumbent in oncology screening and recurrence monitoring, competing for oncologist mind-share and biopharma services revenue.
• Myriad Genetics: Myriad Genetics offers hereditary cancer and tumor profiling tests serving oncologists and urologists. While its focus is broader genetic testing, it competes for the same clinician customers and biopharma partnership economics.

Emerging players

• Tempus AI: Tempus AI combines genomic sequencing with AI-driven analytics for oncology and biopharma customers. Its AI platform, MRD-adjacent offerings, and pharma partnerships overlap with Adaptive's Immune Medicine business in particular.
• Personalis: Personalis is a cancer genomics company offering tumor and immune profiling for biopharma R&D and clinical trials. It overlaps with Adaptive's Immune Medicine/biopharma services segment around TCR-based and immune profiling data for pharma customers.
• Caris Life Sciences: Caris provides molecular profiling and AI-driven oncology diagnostics, including liquid biopsy offerings that overlap with MRD monitoring. It targets similar oncologist and biopharma customer segments and represents an emerging competitor in cancer recurrence testing.

Others

• 10x Genomics: 10x Genomics provides single-cell and immune receptor sequencing tools that enable research applications. It is an enabling/infrastructure provider for the same immune sequencing ecosystem in which Adaptive operates rather than a direct competitor in MRD.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Adaptivebiotech
• Facebookfacebook.com/125974454184631
• LinkedInlinkedin.com/company/adaptive-biotechnologies-corp-
• Instagraminstagram.com/adaptivebiotech

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds13 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adaptive Biotechnologies